Neoplasms

Blood and Lymph Conditions

All Conditions

Rare Diseases

Polycythemia Vera

Polycythemia

Hematologic Diseases

Bone Marrow Neoplasms

Hematologic Neoplasms

Bone Marrow Diseases

Myeloproliferative Disorders

Chronic Myeloproliferative Disorders

XL019

The purpose of this study is to evaluate the safety and tolerability of the JAK2 inhibitor XL019 administered orally in adults with Polycythemia Vera.

A Phase 1 Study of XL019 in Adults With Polycythemia Vera

A Phase 1 Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL019 Administered to Subjects With Polycythemia Vera

Exelixis

Heart and Blood Diseases

Primary Myelofibrosis

Thrombocytosis

Thrombocythemia, Essential

Blood Platelet Disorders

Hemostatic Disorders

Blood Coagulation Disorders

Hemorrhagic Disorders

gelatin capsules supplied in 5-mg, 25-mg, and 100-mg strengths

The purpose of this study is to evaluate the safety and tolerability of XL019 in adults with myelofibrosis. XL019 is a selective inhibitor of the cytoplasmic tyrosine kinase JAK2. JAK2 is activated by cytokine and growth factor receptors and phosphorylates members of the STAT family of inducible transcription factors. Activation of the JAK/STAT pathway promotes cell growth and survival, and is a common feature of human tumors. JAK2 is activated by mutation in the majority of patients with myelofibrosis, polycythemia vera and essential thrombocytosis and appears to drive the inappropriate growth of blood cells in these conditions.

A Safety Study of XL019 in Adults With Myelofibrosis

A Phase 1 Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL019 Administered to Subjects With Myelofibrosis

Chunyan Song, MD/Senior Manager, Clinical Research

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
A Phase 1 Study of XL019 in Adults With Polycythemia Vera	NCT00595829	Polycythemia Ve...	XL019	18 Years -	Exelixis
A Phase 1 Study of XL019 in Adults With Polycythemia Vera	NCT00595829	Polycythemia Ve...	XL019	18 Years -	Exelixis
A Safety Study of XL019 in Adults With Myelofibrosis	NCT00522574	Myeloproliferat... Myelofibrosis Polycythemia Ve... Thrombocythemia...	XL019	18 Years -	Exelixis

Spots Global Cancer Trial Database for xl019

Every month we try and update this database with for xl019 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for xl019

Every month we try and update this database with for xl019 cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for xl019 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.